



Sienna Cancer Diagnostics Limited
ABN 74 099 803 460

1 Dalmore Drive
Scoresby VIC 3179

Tel: +61 3 8288 2141
Fax: +61 3 8288 2059

2 August 2017

PRE-QUOTATION DISCLOSURE ANNOUNCEMENT

Sienna Cancer Diagnostics Limited ACN 099 803 460 (Sienna) completes IPO and ASX listing

- Sienna has successfully closed its IPO capital raising - having received applications for \$4,597,600 million.
- Official quotation of Sienna's fully paid ordinary shares on the ASX Limited (ASX) will commence Thursday 3 August 2017.

Melbourne, 2 August 2017: Sienna Cancer Diagnostics Limited (ASX:SDX) has successfully closed its capital raising under its IPO prospectus, having received applications for \$4,597,600.

The following information is given for release to the market in connection with the commencement of official quotation of Sienna's fully paid ordinary shares on the Official List of the ASX Limited.

Unless otherwise defined in this notice, capitalised terms used in this notice have the meanings given to them in the prospectus lodged by Sienna with the Australian Securities and Investment Commission (ASIC) on 25 May 2017 (Prospectus).

1. Close of IPO Offer and issue of shares

Sienna confirms its IPO Offer has closed and that:

- Sienna has now issued 22,988,000 fully paid ordinary shares to successful IPO applicants under its Prospectus at an issue price of \$0.20 per share;
- Sienna has an appropriate spread of shareholders being at least 300 non-affiliated security holders, each of whom holds a parcel of shares that are not restricted securities or subject to voluntary escrow with a value of at least \$2,000;
- Sienna has demonstrated a free float of at least 20%;
- Sienna has despatched holding statements to all shareholders including holdings on the CHESS sub-register and those that are issuer sponsored; and
- No money was required to be refunded to any IPO prospectus applicant.

2. Capital structure and escrow

With completion of the IPO allotments under the Prospectus, Sienna's share capital will consist of 180,262,327 fully paid ordinary shares.

As part of the admission of Sienna to the ASX Official List, restriction agreements have been entered into by certain shareholders under which trading in the following securities is limited for a period of 24 months from the date of Sienna's ASX Listing. Details of those security holders are set out below:

For personal use only

Holder of Securities	Number of shares	Number of options
David Neate	5,670,743	600,000
Geoff Cumming	237,225	600,000
David Earp	33,334	400,000
Carl Stubbings	28,494	400,000
Geron Corporation	13,842,625	0
Board of Regents of the University of Texa System	4,614,208	0
Matthew Hoskin	0	2,500,000
Grand total	24,426,629	4,500,000

3. Working capital / financial position

Use of Funds*	Subscription Amount \$4,598,000#
Complete additional clinical studies and undertake sales and marketing activities to increase the uptake of the IVD product in the bladder cancer application	(\$1,583,000)
Business development to expand the use of the IVD geographically	(\$282,000)
Internal and external research and development to validate additional clinical applications	(\$1,592,000)
Introduction of new technologies to the Company's product pipeline	(\$1,022,000)
Capital purchases	(\$158,000)
Anticipated R & D Tax Incentive refunds/interest income	\$1,718,000
Working Capital	(\$1,775,000)
Expenses of the Offer	(\$629,000)
Projected balance of cash at the Closing Date of this Prospectus, prior to the IPO funding	\$725,000
TOTAL	(\$4,598,000)

Note: The \$4,598,000 raised through the IPO is anticipated to provide the Company with sufficient working capital for the next 19 months. Although Sienna has been receiving product income since January 2015, the Company has not allowed for the receipt of any product income in the above calculation. If the monthly average of product income achieved during the 2016 financial year was included, approximately \$1.1 million additional funding would be received and this would provide the Company with a further 3 months of working capital.

The Company confirms there has been no material change to the financial position as outlined in the Prospectus (other than in the ordinary course of business) or to the expenditure program as outlined in the Prospectus.

The Directors reaffirm the statement made in the Prospectus that, in the opinion of the Directors, on completion of the Sienna IPO Offer, Sienna will have sufficient working capital to carry out its objectives as stated in the Prospectus.

4. Pro Forma Statement of Financial Position

The pro forma statement of financial position as at 31 December 2016 has been prepared to illustrate the effects of the IPO's financial transactions (the \$4,597,600 of new capital raised and associated costs) on the Company's financial position.

	Reviewed	Subscription	
		Adjustments	Pro forma
As at 31 December 2016	\$	\$	\$
Current Assets			
Cash assets	1,654,083	3,968,000	5,622,083
Receivables	76,511	–	76,511
Other assets	26,239	–	26,239
Total Current Assets	1,756,833	3,968,000	5,724,833
Non-Current Assets			
Intangibles	2,314,362	–	2,314,362
Property, plant and equipment	36,109	–	36,109
Total Non-Current Assets	2,350,471	–	2,350,471
Total Assets	4,107,304	3,968,000	8,075,304
Current Liabilities			
Payables	427,185	–	427,185
Provisions	65,668	–	65,668
Total Current Liabilities	492,853	–	492,853
Non-Current Liabilities			
Provisions	15,166	–	15,166
Total Non-Current Liabilities	15,166	–	15,166
Total Liabilities	508,019	–	508,019
Net Assets	3,599,285	3,968,000	7,567,285
Equity			
Contributed Equity	16,670,997	4,257,000	20,927,997
Reserves	113,928	–	113,928
Accumulated losses	(13,185,640)	(289,000)	(13,474,640)
Total Equity	3,599,285	3,968,000	7,567,285

5. Further information

For further detail on any of the matters referred to in this notice please see the Sienna Prospectus available on the ASX website, the pre-listing disclosures made by Sienna or contact your professional adviser.



.....
Dr Geoffrey Cumming
Non-executive Chairman
Sienna Cancer Diagnostics Limited

For personal use only